| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc. | Sepranolone | Tourette syndrome (TS) | Phase 2b | Ongoing | Subcutaneous | Neurology |
| Relmada Therapeutics Inc. | Sepranolone | Tourette syndrome (TS) | Phase 2b | Ongoing | Subcutaneous | Neurology |
| Relmada Therapeutics Inc. | NDV-01 | Bladder Cancer | Phase 2 | Data Released | Inhalation | Oncology |
| RenovoRx Inc. | RenovoGem - (TIGeR-PaC) | Locally advanced pancreatic cancer (LAPC) | Phase 3 | Data Released | Intra-arterial | Oncology |
| RenovoRx Inc. | RenovoGem - (CouGar) | Unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA) | Phase 3 | Enrollment Initiation | Intra-arterial | Oncology |
| RenovoRx Inc. | RenovoGem | Cholangiocarcinoma (bile duct cancer) or eCCA | Phase 2/3 | Ongoing | Intra-arterial | Oncology |
| Repare Therapeutics Inc. | Lunresertib (RP-6306) + Debio 0123 - (MYTHIC) | Solid Tumors | Phase 3 | Trial Planned | Oral | Oncology |
| Repare Therapeutics Inc. | RP-3500 - (TRESR) | Solid tumors | Phase 2 | Enrollment Initiation | Oral | Oncology |